Countries
Industry
Startup stage
Startup size
Funding
Impact startup SDGs
Showing: 11321 filtered startups

Findex

Findex makes the modern private banking experience accessible through a unified digital asset management platform — powered by AI. We enable you to track, optimize, and grow your net worth with full transparency, intelligent insights, and a smarter way to manage your financial future. Founded in 2022 in Gothenburg, Sweden, Findex emerged from a simple insight: investors deserve a single platform for all asset classes. Our founders set out to build a solution for every type of investor — a place where you can manage and understand your entire financial landscape, no matter where you are in your journey. Traditionally, the private banking experience has been reserved for high-net-worth individuals. We want to change that. Findex democratizes access by bringing advanced tools, clarity, and knowledge-sharing to a broader audience, encouraging better financial decisions through diversified investing. Beyond personal portfolio management, Findex also empowers private companies with integrated investor-relations tools — from shareholder and equity management to communication and secure document handling. For partners, our platform opens the door to tailored, data-driven capital opportunities through curated investment networks and strategic integrations. As we build on the foundation created for investors, we are expanding Findex with new modules that unlock additional value across the market. Our vision is an investment ecosystem — a portal for financial knowledge, connected opportunities, and a more accessible, intelligent way to build wealth. "The modern private banking experience powered by AI – track, optimize, and grow your net worth in one platform."

Plateful

Our mission is to help food manufacturers reduce food waste and cost through our digital platform. To date, we've successfully transacted over 4.000 tons of food, and we're continuing to scale our business to have an even greater impact. We have ambitious growth plans and are expanding. We recently carried out a rebranding and are in the process of building our product & technology team to scale further.

Baby Journey

Baby Journey is one of the hottest baby-tech companies in Scandinavia. Our mission is to build a data-driven digital universe supporting pregnant women, parents and families with everything there is to know about pregnancy, childbirth and the daily life with kids. Through our mobile app, www.babyjourney.se, as well as our social media channels, we also help companies to build brand awareness towards Baby Journey's users and followers. Each month our app is growing with 8000 active users and our website is rapidly increasing the amount of unique visitors. Today we are more than 20 employees at our HQ in Stockholm. We are constantly growing our team with new colleagues so don't hesitate to reach out if you are interested of joining our journey!

myPallet

With myPallet’s digital transport packaging management, you can register both incoming and outgoing transport packaging in less than 10 seconds. Regardless whether EUR pallets, CC containers, Meat boxes or other types of transport packaging. myPallet is an open system and our vision is to become a market-neutral industry standard. With the myPallet app, you have complete self-control and no wastage. Your balance is automatically updated in real time and your transaction is visible a few seconds later in the web portal. The myPallet app can be downloaded on both iOS or Android devices and compatible to both mobile, tablet and PDA. The web portal is accessed via your web browser. With the myPallet app you eliminate all paper forms as well as the heavy manual administration work! By reusing your transport packaging, your company also helps to take great responsibility for the environment.

Enernite AS

Enernite is a technology company founded on the belief that data insights and digital solutions could accelerate the renewable energy revolution. We enable energy developers to make data-driven decisions in the early screening phase of renewable energy projects. To make this happen we automate the information gathering from fragmented sources and produce unique data sets based on satellite imagery analysis.

Solstorm Rocket Propulsion

Solstorm Rocket Propulsion makes the next generation of rocket engines using hybrid propulsion technology and 3d-printed fuel cellsAs the market for commercial space industries matures we are seeing smaller and smaller satellites being built and with it, increasing demand for small satellite launchers providing dedicated launchesAs existing engines are mainly developed by government agencies, military providers with non-export policies, and competing launch vehicle providers, most market entrants are forced to develop all their own engine designs from scratch. This is a major bottleneck in the development of smaller launch vehicles, forcing every actor to go through the same R&D process before they can perform their actual business services. By providing a commercially available off-the-shelf rocket engine design for the launch vehicle's upper stage, we want to save these launch companies the initial years of testing and research needed, letting our customers skip the r&d-heavy initial process of engine development and go straight to value-generating satellite launches. Reducing the time from inception to launch by several years, we relieve rocket launcher companies of the insecurity and stress related to the development of rocket engines and let them go straight to launch, bringing more cargo to orbit.

Material Mapper AS

Material Mapper’s vision is to create a market of scale for secondary building materials by mapping them in Europe and leading the transition towards a closed-loop circular construction and demolition industry. The European construction industry is urgently lacking clear, centralized access to information about secondary building materials available in their area, due to the fragmentation and inconsistency with which these public data are captured and stored. This makes building planning with quality secondary building materials time and cost-intensive for stakeholders, in turn making it difficult to comply with the EU’s Waste Directive of 70% recycled/re-used building materials. Our young, multi-award-winning company is planning to launch a project over 24 months to build a breakthrough innovation for the whole of Europe using artificial intelligence and machine learning that will extract, read, evaluate, and forecast quantities of secondary building materials for the user, making future planning for property developers seamless through our platform. We are confident that our product is unique and that we have no direct competition. By combining our deep technology, partnership development, and B2B sales expertise, we are already working closely with major industry actors to harness insights and their existing networks for our customer base.

Apotek 1

Apotek 1 er Norges største apotekkjede og vi er i stadig vekst. Hos oss jobber ca. 3500 dedikerte medarbeidere, og vi er også landets største farmasøytiske arbeidsgiver. Vi har en stolt kultur med klare ambisjoner om alltid å leve opp til vårt slagord 'Vår kunnskap - din trygghet' i våre kundemøter. Kompetanse og kvalitet er kjernen for vår virksomhet, og derfor er faglig og personlig videreutvikling av våre medarbeidere helt sentralt i kjeden. I Apotek 1 er vi opptatt av å etterleve våre verdier som er: pålitelig, frisk, engasjert og nær. Vi bestreber at dette skal prege alle ansatte, alle beslutninger, alle handlinger og alle mål i selskapet. Apotek 1 Gruppen AS er eiet av den tyske Phoenix-gruppen. Servicekontor og distribusjonsenhet ligger på Lørenskog i Akershus. Vi er landets største leverandør av legemidler pakket i multidose, samt legemidler og tjenester til kommunehelsetjenesten, blant annet legemiddelgjennomganger.

SquarePeg AS

Apple made one of the most iconic ads “Here’s to the crazy ones” to lift their campaign “Think Different” in 1997. This ad was so “new” and controversial that it since has made history, and is now part of most curriculum in most marketing schools around the globe. It was written by Rob Siltanen, Creative Director for TBWA/Chiat/Day and Creative Director at Apple Lee Clow. It wasn’t Steve Jobs, but it was he who made the quote famous (Originally it was the voice of Richard Dreyfuss in the ad). This, for us marketing geeks, is food for thought, awe and inspiration. Not because of the text itself, Steve as a celebrity, but for what impact that ad had on its audience. Knowing now, in retrospect, the ad was basically describing Steve himself, and beautifully put together with famous “rebels” of their field, we cannot help empathizing and relate to the ad, the history and the text. Don’t get us wrong, we are no rebels. We do not contribute to any groundbreaking tech innovation or have a goal of changing the world. What we believe in, is changing the way advertising is perceived, consumed, and targeted. The glory days of “buying a TV ad and you’re set” have long passed. The effect of “Here’s to the crazy ones” can still be archived, and is our goal in everything we do. We are forever inspired by Steve Jobs, and his rebel being, and we named our company after his ad, written by an agency. The agency does not matter, the sender does.

iO Data AS

iO Data is here to help companies build their digital businesses. Only 33% of companies rate their level of digitalization as advanced today, but 70% expect they will get there by 2020¹. This transformation process will be critical for future success. Our core business is hosting, conversion, QC, and accessibility of Big Data. Bundled with Security Audits, Embedded Development, Destruction, Consultancy, and Innovation.

Justify

Today, legal services are provided on the premises of the legal industry. We believe in making legal services available to everyone. We do this by automating legal processes by connecting law with design and technology. So that more people are able to be their own lawyers. We are testing our solutions in the Norwegian market at the moment, but all services are built to scale internationally. Stay tuned to receive more info when the legal products built to provide access to justice is ready to launch.

PCU Company

Demand for peronal-safe biometric-IDs. If connected you can be hacked and if your IDs are stolen you are digitally-dead. Mobiles and web surveillance are recording our face, fingers and iris pictures. IDs for banking, trade and health must be separated from all the data stored at big-data, governments, secret-services, criminals and social medias. As it is not possible to secure our biometric-IDs 100% we just make stealing IDs not worthwhile. How do we do that? With Cybi-key create your safe Cyber-biometric-IDs from our digital twins. Cybi-IDs the trusted id payment missing today.

Nordic Beverage Solutions

Get your products from the manufacturer to the end customer in the fastest and easiest way possible. Regardless of existing volume or size - NBS provides you with the sales channels, systems, and logistics to reach the whole of Norway. IT-system One system for product registration, sales, statistics, and inventory for your products. Fully integrated with all the services you need. Logistics Efficient logistics from a central warehouse in Vestby of 5,500 m2 specially built for handling beverages. Sales to all channels Sell ​​your products under 4.7% alcohol to private customers through Lokalbrygg.no, over 4.7% alcohol to Vinmonopolet, and everything to HoReCa through horecalevering.no. Marketing and Fairs Increase your visibility through our own fairs for HoReCa, private customers, and Vinmonopolet.

Seald AS

Bile duct cancer is an aggressive form of cancer with an extremely poor overall five-year survival rate of just 2-5 %. Classified as an orphan disease, annual incidence in Europe and the United States of 15-22,000 patients, and a significantly higher incidence in Asia, makes it a major player and the deadliest of the gastrointestinal cancers. Only a small number of patients are eligible for a complete surgical resection by local resection or liver transplantation, and more than 50% of these relapse. The vast majority are treated by gemcitabine-based palliative chemotherapy with a life expectancy of 11 months, and five-year survival rate of zero %. Thus, there is an urgent and unmet medical need to develop new and better treatment strategies for these patients. The innovations developed by Seald are a result of adopting a multidisciplinary approach to the diagnosis and treatment of bile duct cancer, based on extensive drug sensitivity assays on living cancer cells, molecular biomarkers, DNA sequencing, extensive bioinformatics analyses and zebrafish models. Sealds’s holistic approach is unique with possible modes of action that can be used on other solid cancers. Our technology includes drug repurposing and innovation on new medical substances, diagnostics and methodology. The stipulated pharma market globally is USD 2.1-4.2 billion, in addition to the markets for diagnostics and platform technology

Pharmasum Therapeutics AS

New drugs for treating diseases of Down syndrome. More than 1% of the global GDP is spent on nursing demented people, and the number requiring nursing will triple within 2050. The disease is progressive, leading to death. There is no current cure available, only symptomatic treatments. Individuals born with Down syndrome have a more than 10x risk of developing dementia as well as a host of other diseases including diabetes. Our drug target, DYRK1A is an enzyme found on chromosome 21, and is considered a key factor determining developmental and medical challenges faced by individuals with Down. The enzyme interacts with multiple biological mechanisms involved in Alzheimer’s and autoimmune diseases. Advanced drug designUsing advanced drug design technologies, we have designed a potent DYRK1A inhibitor drug, PST-900. A use and substance of matter patent have been applied for. The company is currently working on chemical Lead Optimisation with 8 full-time medicinal chemists contracted.Financing and milestonesThe Company raised NOK 5 million in 2015 and 8.8 MNOK in 2016/2017, matching non-dilutive research (BIA) and business grants (Innovation Norway). We demonstrated Proof of Principle in a model system for Alzheimer’s disease in 2Q2016. We have also demonstrated that our drug is capable of reversing diabetes in an animal model. Together with clinical and regulatory advisors, we have identified an important unmet need for a drug to treat newly diagnosed diabetes. We will use this indication to quickly progress to market and from there develop analogous drug molecules in Alzheimer’s disease, focused especially in Down syndrome. Funding soughtThe current funding round will raise 15+ MNOK to fund the progression to the final Development Candidate during 2018. Following this, further funding will be sought to perform toxicology/safety and Phase 1 clinical studies. A highly experienced teamThe team behind Pharmasum Therapeutics have broad, international pharmaceutical and biotechnology experience, and is supported by an excellent group of advisors. Anders Fugelli, Ph.D., CEO. John Sigurd Svendsen, Ph.D., CSO. Pauline Stewart-Long, Ph.D. Project Management. Henning Mork, CFO. Board of Directors: Andrew Parsons, PhD. Øystein Soug, MSc. Mark Treherne, PhD, John Sigurd Svendsen, PhD.